Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5881793 | 0.91 | CNR2 (0.73) | CNR2CNR1 | |
| SCHEMBL5881647 | 0.90 | CNR2 (0.74) | CNR2CNR1 | |
| SCHEMBL5881594 | 0.87 | CNR2 (0.70) | CNR2CNR1 | |
| SCHEMBL5881735 | 0.83 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL6670375 | 0.81 | CNR2 (0.51) | CNR2CNR1 | |
| SCHEMBL5881753 | 0.81 | CNR2 (0.51) | CNR2CNR1 | |
| SCHEMBL6670371 | 0.81 | CNR2 (0.52) | CNR2CNR1 | |
| SCHEMBL5881563 | 0.80 | CNR2 (0.46) | CNR2CNR1 | |
| SCHEMBL5881671 | 0.80 | CNR2 (0.50) | CNR2CNR1 | |
| SCHEMBL5881766 | 0.80 | CNR2 (0.68) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135554-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | US | disclosed |
| US-7030139-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-04-18 | — | — | US | disclosed |
| US-20040116465-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
| EP-1390350-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002085866-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135554-A1 | Novel compounds | OPRL1, OPRK1, TRPV1 | CNR2 21/4885CNR1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.